JP6479685B2 - 病原性細菌生育の抑制のための組成物および方法 - Google Patents

病原性細菌生育の抑制のための組成物および方法 Download PDF

Info

Publication number
JP6479685B2
JP6479685B2 JP2015556240A JP2015556240A JP6479685B2 JP 6479685 B2 JP6479685 B2 JP 6479685B2 JP 2015556240 A JP2015556240 A JP 2015556240A JP 2015556240 A JP2015556240 A JP 2015556240A JP 6479685 B2 JP6479685 B2 JP 6479685B2
Authority
JP
Japan
Prior art keywords
clostridium
bacteria
bacterial
composition
spore
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015556240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509002A (ja
JP2016509002A5 (OSRAM
Inventor
エヌ クック デイビッド
エヌ クック デイビッド
ジャーン ハン
ジャーン ハン
エム ドノフリオ アンソニー
エム ドノフリオ アンソニー
エイ ベリー デイビッド
エイ ベリー デイビッド
ジェーン ランバルド マッケンジー メリー
ジェーン ランバルド マッケンジー メリー
ジー オーニス ジョン
ジー オーニス ジョン
マッケンジー グレゴリー
マッケンジー グレゴリー
オオスミ トシロウ
オオスミ トシロウ
Original Assignee
セレス セラピューティクス インコーポレイテッド
セレス セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレス セラピューティクス インコーポレイテッド, セレス セラピューティクス インコーポレイテッド filed Critical セレス セラピューティクス インコーポレイテッド
Publication of JP2016509002A publication Critical patent/JP2016509002A/ja
Publication of JP2016509002A5 publication Critical patent/JP2016509002A5/ja
Priority to JP2019020032A priority Critical patent/JP6908332B2/ja
Application granted granted Critical
Publication of JP6479685B2 publication Critical patent/JP6479685B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2015556240A 2013-02-04 2014-02-04 病原性細菌生育の抑制のための組成物および方法 Active JP6479685B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019020032A JP6908332B2 (ja) 2013-02-04 2019-02-06 病原性細菌生育の抑制のための組成物および方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201361760574P 2013-02-04 2013-02-04
US201361760606P 2013-02-04 2013-02-04
US201361760585P 2013-02-04 2013-02-04
US201361760584P 2013-02-04 2013-02-04
US61/760,606 2013-02-04
US61/760,574 2013-02-04
US61/760,584 2013-02-04
US61/760,585 2013-02-04
US201461926918P 2014-01-13 2014-01-13
US61/926,918 2014-01-13
PCT/US2014/014744 WO2014121301A1 (en) 2013-02-04 2014-02-04 Compositions and methods for inhibition of pathogenic bacterial growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019020032A Division JP6908332B2 (ja) 2013-02-04 2019-02-06 病原性細菌生育の抑制のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2016509002A JP2016509002A (ja) 2016-03-24
JP2016509002A5 JP2016509002A5 (OSRAM) 2017-03-09
JP6479685B2 true JP6479685B2 (ja) 2019-03-06

Family

ID=51263061

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015556240A Active JP6479685B2 (ja) 2013-02-04 2014-02-04 病原性細菌生育の抑制のための組成物および方法
JP2015556241A Pending JP2016509003A (ja) 2013-02-04 2014-02-04 組成物および方法
JP2019020032A Active JP6908332B2 (ja) 2013-02-04 2019-02-06 病原性細菌生育の抑制のための組成物および方法
JP2019034615A Active JP6942745B2 (ja) 2013-02-04 2019-02-27 組成物および方法
JP2021110109A Active JP7409743B2 (ja) 2013-02-04 2021-07-01 病原性細菌生育の抑制のための組成物および方法
JP2023212983A Pending JP2024045100A (ja) 2013-02-04 2023-12-18 病原性細菌生育の抑制のための組成物および方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015556241A Pending JP2016509003A (ja) 2013-02-04 2014-02-04 組成物および方法
JP2019020032A Active JP6908332B2 (ja) 2013-02-04 2019-02-06 病原性細菌生育の抑制のための組成物および方法
JP2019034615A Active JP6942745B2 (ja) 2013-02-04 2019-02-27 組成物および方法
JP2021110109A Active JP7409743B2 (ja) 2013-02-04 2021-07-01 病原性細菌生育の抑制のための組成物および方法
JP2023212983A Pending JP2024045100A (ja) 2013-02-04 2023-12-18 病原性細菌生育の抑制のための組成物および方法

Country Status (13)

Country Link
US (14) US10064900B2 (OSRAM)
EP (5) EP3587558A3 (OSRAM)
JP (6) JP6479685B2 (OSRAM)
KR (3) KR102553134B1 (OSRAM)
CN (2) CN110917220A (OSRAM)
AU (7) AU2014212003C1 (OSRAM)
BR (2) BR112015018625A2 (OSRAM)
CA (2) CA2899926C (OSRAM)
HK (3) HK1218559A1 (OSRAM)
MX (2) MX369877B (OSRAM)
NZ (1) NZ711771A (OSRAM)
RU (1) RU2664479C2 (OSRAM)
WO (3) WO2014121302A2 (OSRAM)

Families Citing this family (352)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
HRP20220751T1 (hr) 2010-02-01 2022-09-02 Rebiotix, Inc. Bakterioterapija clostridium difficile kolitisa
US9181593B2 (en) 2010-02-17 2015-11-10 Gen-Probe Incorporated Compositions and methods to detect Atopobium vaginae nucleic acid
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
NZ607043A (en) 2010-08-04 2015-05-29 Borody Thomas J Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10085938B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
CN103561752B (zh) 2011-03-09 2016-04-20 明尼苏达大学评议会 用于移植结肠微生物群的组合物和方法
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US10238694B2 (en) 2011-12-01 2019-03-26 The University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
US9173910B2 (en) 2012-02-29 2015-11-03 The General Hospital Corporation Compositions of microbiota and methods related thereto
EP2825676B1 (en) 2012-03-17 2017-12-20 The Regents of The University of California Fast diagnosis and personalized treatments for acne
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
JP6203816B2 (ja) 2012-03-29 2017-09-27 セラバイオーム，エルエルシー 回腸及び虫垂に対して活性の胃腸部位特異的経口ワクチン接種製剤
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
JP2015522554A (ja) 2012-06-04 2015-08-06 サンコー・エナジー・インコーポレーテッド パラフィン油及び沈降防止剤を含む製剤
US10220089B2 (en) 2012-08-29 2019-03-05 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
EP3628161B1 (en) 2012-11-23 2023-04-05 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CA2899926C (en) 2013-02-04 2025-11-18 Seres Therapeutics, Inc. DIGESTIVE TUBE FILLING COMPOSITIONS
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
CA3013541C (en) 2013-03-14 2021-01-19 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
EP2967077A4 (en) 2013-03-15 2016-09-14 Seres Therapeutics Inc NETWORK-BASED MICROBIAL COMPOSITIONS AND METHOD
ES2664411T3 (es) 2013-03-15 2018-04-19 Suncor Energy Inc. Composiciones herbicidas
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
HRP20181302T1 (hr) 2013-06-05 2018-11-02 Rebiotix, Inc. Terapija za obnavljanje mikrobiota (mrt), pripravci i postupci proizvodnje
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12318377B2 (en) 2013-12-20 2025-06-03 Seed Health, Inc. Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
AU2015227075A1 (en) * 2014-03-06 2016-09-22 Ohio State Innovation Foundation Probiotic formulations and methods for use
US9783858B2 (en) * 2014-04-02 2017-10-10 Northwestern University Altered microbiome of chronic pelvic pain
US10766799B2 (en) 2014-05-23 2020-09-08 Nch Corporation Method for improving quality of aquaculture pond water using a nutrient germinant composition and spore incubation method
FI127671B (en) 2014-05-28 2018-11-30 Filip Scheperjans Method for diagnostics of Parkinson’s disease
US20160016002A1 (en) * 2014-07-17 2016-01-21 John Todd Kuenstner Treatment of Diseases Using Combination of Ultraviolet Blood Irradiation and Probiotics
HUE038212T2 (hu) * 2014-07-25 2018-10-29 Biosynth Srl Többszörös beépített epitópokat kifejezõ molekuláris konstrukt bázikus egységeket tartalmazó glikokonjugátum vakcinák enteropatogén baktériumok által okozott fertõzések elleni szélesspektrumú vakcina elõállításához
KR102530120B1 (ko) * 2014-08-04 2023-05-12 바스프 에스이 항진균성 파에니바실러스 균주, 푸사리시딘-유형 화합물, 및 이의 용도
US10900043B2 (en) 2014-09-02 2021-01-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating bacterial disease
US10286016B2 (en) 2014-09-02 2019-05-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating gonorrhea
CA2959414C (en) 2014-09-05 2023-03-14 Symbiomix Therapeutics, Llc Secnidazole for use in the treatment of bacterial vaginosis
WO2016057671A1 (en) * 2014-10-07 2016-04-14 University Of Virginia Patent Foundation Compositions and methods for preventing and treating infection
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
WO2016065075A1 (en) 2014-10-21 2016-04-28 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
AU2015339284B2 (en) 2014-10-30 2021-08-05 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
CA2966363A1 (en) * 2014-10-30 2016-05-06 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
GB2551642B (en) 2014-10-31 2020-09-23 Pendulum Therapeutics Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
FI3223835T3 (fi) * 2014-11-25 2025-06-16 Memorial Sloan Kettering Cancer Center Suolen mikrobisto ja gvhd
WO2016105498A1 (en) 2014-12-23 2016-06-30 Synthetic Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
CA2971108C (en) 2014-12-23 2019-09-17 4D Pharma Research Limited A bacteroides thetaiotaomicron strain and use thereof in reducing inflammation
HRP20180847T1 (hr) 2014-12-23 2018-08-24 4D Pharma Research Limited Pirinski polipeptid i imunološka modulacija
WO2016103005A1 (en) 2014-12-23 2016-06-30 Institut Pasteur Method of culturing segmented filamentous bacteria in vitro
WO2016126954A1 (en) * 2015-02-06 2016-08-11 Western University Of Health Sciences Probiotic compositions and methods of use
KR20170122776A (ko) 2015-03-06 2017-11-06 신세틱 바이오로직스, 인코퍼레이티드 마이크로바이옴 보호를 위한 안전하고 유효한 베타-락타마제 투약
CA2979086A1 (en) * 2015-03-12 2016-09-15 The University Of British Columbia Bacterial compositions and methods of use thereof
SG11201706961RA (en) * 2015-03-16 2017-09-28 Ecole Polytechnique Fed De Lausanne (Epfl) Archaebacteria in bioactive animal feed, method of making the composition and methods employing the composition
CN107849564A (zh) * 2015-04-03 2018-03-27 奎斯特诊断投资股份有限公司 用于检测致病性钩端螺旋体菌株的测定
EP3283084B1 (en) * 2015-04-13 2025-08-06 Psomagen, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
EP3283086A4 (en) * 2015-04-13 2019-04-24 Ubiome Inc. METHOD AND SYSTEM FOR MICROBIOMY-DERIVED DIAGNOSTICS AND THERAPEUTIC FOR DISEASES RELATED TO MICROBIOMIC FUNCTIONAL PROPERTIES
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions
CN107708716B (zh) * 2015-04-13 2022-12-06 普梭梅根公司 用于微生物组分类学特征相关的状况的微生物组来源的诊断和治疗的方法及系统
EP3283087A4 (en) * 2015-04-14 2019-03-13 Ubiome Inc. METHOD AND SYSTEM FOR MICROBIOMEDIVED DIAGNOSTICS AND THERAPEUTICS FOR DISEASES OF THE ENDOCRINE SYSTEM
FR3035317B1 (fr) 2015-04-24 2019-06-14 Maat Pharma Dispositif de prelevement de micro-organismes, kit de prelevement comprenant un tel dispositif et procede de prelevement mettant en œuvre un tel dispositif
FR3035328B1 (fr) 2015-04-24 2019-08-23 Maat Pharma Procede de preparation d'un echantillon de microbiote fecal
US12050161B2 (en) 2015-04-24 2024-07-30 Maat Pharma Microorganism sampling method, microorganism sampling device and sampling kit comprising such a sampling device
WO2016183577A1 (en) * 2015-05-14 2016-11-17 Crestovo Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
CN108243608A (zh) * 2015-05-22 2018-07-03 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
CA2988082C (en) 2015-06-01 2020-09-29 Symbiomix Therapeutics, Llc Novel nitroimidazole formulations and uses thereof
CN105067731B (zh) * 2015-06-05 2017-06-16 中国农业科学院兰州兽医研究所 一种弓形虫感染后血清中生物标记物的筛选方法及筛选出的生物标记物的应用
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
IL281424B2 (en) * 2015-06-09 2023-10-01 Rebiotix Inc Microbiota restoration treatment preparations and production methods
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
JP6439037B2 (ja) 2015-06-15 2018-12-19 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
MA41010B1 (fr) * 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HUE045413T2 (hu) 2015-06-15 2019-12-30 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
ES2753779T3 (es) * 2015-06-15 2020-04-14 4D Pharma Res Ltd Blautia stercosis y wexlerae para la utilización en el tratamiento de enfermedades inflamatorias y autoinmunes
US10851399B2 (en) 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
US10632157B2 (en) 2016-04-15 2020-04-28 Ascus Biosciences, Inc. Microbial compositions and methods of use for improving fowl production
AU2016282996A1 (en) 2015-06-25 2018-01-18 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
US9938558B2 (en) 2015-06-25 2018-04-10 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
RU2018103081A (ru) * 2015-07-08 2019-08-08 Серес Терапеутикс, Инк. Способы лечения колитов
HK1255383A1 (zh) 2015-07-31 2019-08-16 The Research Institute At Nationwide Children's Hospital 去除生物膜的肽及抗體
EP3341000A4 (en) * 2015-08-24 2019-02-20 Nubyiota LLC SYSTEMS AND METHOD FOR TREATING DYSBIOSIS WITH BACTERIAL POPULATIONS FROM FECALIA
WO2017041039A1 (en) * 2015-09-04 2017-03-09 Memorial Sloan-Kettering Cancer Center Methods and compositions for detecting risk of cancer relapse
AU2016321333A1 (en) * 2015-09-09 2018-04-26 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with cerebro-craniofacial health
WO2017053544A1 (en) * 2015-09-22 2017-03-30 Mayo Foundation For Medical Education And Research Methods and materials for using biomarkers which predict susceptibility to clostridium difficile infection
JP2018535653A (ja) * 2015-09-24 2018-12-06 アグリカルチャー ビクトリア サービシーズ プロプライエタリー リミテッド ブラキナリア属内生菌及び関連する方法
RU2709464C2 (ru) 2015-09-29 2019-12-18 Кимберли-Кларк Ворлдвайд, Инк. Синергическая композиция для сохранения здорового баланса микрофлоры
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
IL277648B2 (en) * 2015-11-03 2023-04-01 Brigham & Womens Hospital Inc Medical microbiota for the treatment and/or prevention of food allergy
HUE036362T2 (hu) 2015-11-20 2018-07-30 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
KR20180083894A (ko) * 2015-11-24 2018-07-23 세레스 테라퓨틱스, 인코포레이티드 설계된 박테리아 조성물
US11529412B2 (en) 2015-11-30 2022-12-20 Seed Health, Inc. Method and system for protecting honey bees from pesticides
US10568916B2 (en) 2015-11-30 2020-02-25 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US10933128B2 (en) 2015-11-30 2021-03-02 Joseph E. Kovarik Method and system for protecting honey bees from pesticides
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
US10675347B2 (en) 2015-11-30 2020-06-09 Joseph E. Kovarik Method and system for protecting honey bees from fipronil pesticides
US10086024B2 (en) 2015-11-30 2018-10-02 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
WO2017100420A1 (en) * 2015-12-08 2017-06-15 Mayo Foundation For Medical Education And Research Biomarkers for predicting clostridium difficile infection treatment outcome
FR3045383B1 (fr) * 2015-12-18 2019-06-14 Maat Pharma Procede de lyophilisation d'un echantillon de microbiote fecal
US9993507B2 (en) 2016-01-07 2018-06-12 Ascus Biosciences, Inc. Methods of improving milk production and compositional characteristics
CN106974940B (zh) * 2016-01-15 2020-08-25 深圳华大生命科学研究院 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
FI3639834T3 (fi) * 2016-02-04 2023-09-27 Univ Gent Mikrobiyhteisöjen käyttö ihmisen ja eläimen terveyttä varten
WO2017137834A1 (en) * 2016-02-08 2017-08-17 University Of Oslo Bacterial growth media
EP3205209A1 (en) 2016-02-09 2017-08-16 Basf Se Mixtures and compositions comprising paenibacillus strains or metabolites thereof and other biopesticides
CN115919906A (zh) 2016-03-04 2023-04-07 加利福尼亚大学董事会 微生物聚生体及其用途
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EP3520801A1 (en) 2016-03-04 2019-08-07 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
WO2017160711A1 (en) 2016-03-14 2017-09-21 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
US20170319603A1 (en) * 2016-03-24 2017-11-09 Paratek Pharmaceuticals, Inc. Methods for treating and preventing c. difficile infection
US10897922B2 (en) 2016-04-05 2021-01-26 Nch Corporation Composition and method for germinative compounds in probiotic food and beverage products for human consumption
CA3019732A1 (en) * 2016-04-05 2017-10-12 Nch Corporation Nutrient rich germinant composition and spore incubation method
US12097226B2 (en) 2016-04-05 2024-09-24 Nch Corporation System and method for using a single-serve nutrient spore composition for small scale farm applications
CN116474004A (zh) 2016-04-15 2023-07-25 原生微生物股份有限公司 通过施用微生物聚生体或其纯化菌株来提高禽类的农业生产的方法
EP3445380B3 (en) * 2016-04-19 2025-01-08 Genome Research Limited Bacteriotherapy
AU2017254684A1 (en) 2016-04-21 2018-12-06 Weiss Bioscience, Inc. Compositions and methods for treatment of skin disorders
US10252145B2 (en) 2016-05-02 2019-04-09 Bao Tran Smart device
EP3465212A4 (en) 2016-05-23 2020-01-08 California Institute of Technology REGULAR FLORAL REGULATION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
CN109803534A (zh) * 2016-06-01 2019-05-24 克雷斯顿沃控股公司 用于治疗炎性肠病（ibd）和其他疾病的组合物和方法
ES2960053T3 (es) * 2016-06-14 2024-02-29 Vedanta Biosciences Inc Tratamiento de infección por Clostridium difficile
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
WO2017218889A1 (en) * 2016-06-16 2017-12-21 Ohio State Innovation Foundation Eubacterium probiotics and methods of treating or preventing heart disease
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TW201821093A (zh) * 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201703548D0 (en) * 2017-03-06 2017-04-19 4D Pharma Plc Compositions comprising bacterial strains
CN109475305B (zh) * 2016-07-13 2022-01-25 普梭梅根公司 用于微生物药物基因组学的方法和系统
GB201703552D0 (en) * 2017-03-06 2017-04-19 4D Pharma Plc Compositions comprising bacterial strains
KR101815692B1 (ko) * 2016-07-25 2018-01-16 주식회사 고바이오랩 구강 세균의 군집을 이용한 대사성 질환 진단용 바이오 마커
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
WO2018031545A1 (en) * 2016-08-11 2018-02-15 The Trustees Of The University Of Pennsylvania Compositions and methods for detecting oral squamous cell carcinomas
WO2018046485A1 (en) 2016-09-09 2018-03-15 Swecure Ab Use of butyricimonas and/or oxalobacter for treating irritable bowel syndrome
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
JP6927512B2 (ja) * 2016-10-26 2021-09-01 地方独立行政法人神奈川県立産業技術総合研究所 物体表面の抗菌性試験用菌液媒体
CN110267669A (zh) * 2016-12-06 2019-09-20 潘德勒姆治疗公司 与分离并纯化的微生物有关的方法和组合物
GB201621123D0 (en) * 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US11566238B2 (en) 2016-12-15 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
JP2020501570A (ja) * 2016-12-16 2020-01-23 ヴェダンタ バイオサイエンシーズ インコーポレーテッドＶｅｄａｎｔａ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 細菌完全性を決定するための方法および組成物
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
AU2017381697B2 (en) 2016-12-23 2020-12-24 Keio University Compositions and methods for the induction of CD8+ T-cells
AU2017388535A1 (en) 2016-12-28 2019-07-25 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities with tracer analytics, determination of functional relationships and interactions thereof, and synthesis of microbial ensembles including dosed microbial ensembles and inoculative microbial ensembles
CA3048246A1 (en) 2016-12-28 2018-07-05 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon
US11400121B2 (en) 2017-01-05 2022-08-02 The University Of Chicago Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
CN107058490B (zh) * 2017-01-12 2018-03-06 杨俊杰 肠道及口腔菌群多样性及差异性的分析方法
US10381105B1 (en) 2017-01-24 2019-08-13 Bao Personalized beauty system
WO2018160158A1 (en) * 2017-02-28 2018-09-07 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
US10052026B1 (en) 2017-03-06 2018-08-21 Bao Tran Smart mirror
CA3058943C (en) 2017-04-03 2023-10-17 Gusto Global, Llc Rational design of microbial-based biotherapeutics
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
JP2020513018A (ja) 2017-04-05 2020-04-30 クレストヴォ・ホールディングス・エルエルシー パーキンソン病（ｐｄ）および関連する障害を治療するための組成物および方法
EP3388069B1 (en) 2017-04-12 2019-05-01 ETH Zurich Consortia of living bacteria useful for treatment of microbiome dysbiosis
CA3057692A1 (en) 2017-04-28 2018-11-01 Ascus Biosciences, Inc. Methods for supporting grain intensive and/or energy intensive diets in ruminants by administration of a synthetic bioensemble of microbes or purified strains thereof
US11147792B2 (en) 2017-05-15 2021-10-19 Axial Therapeutics, Inc. Inhibitors of microbially induced amyloid
CA3064171A1 (en) 2017-05-22 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strains
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
WO2018218159A1 (en) 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
SMT202100069T1 (it) 2017-06-14 2021-03-15 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
JP6884889B2 (ja) 2017-06-14 2021-06-09 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
JP2020523326A (ja) 2017-06-14 2020-08-06 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
WO2018236979A1 (en) * 2017-06-20 2018-12-27 Cornell University Probiotic compositions and methods
AU2018309153A1 (en) * 2017-08-04 2020-03-19 Tarunmeet GUJRAL Roseburia hominis, Eubacterium eligens, and combinations thereof as biotherapeutics
CN107854495B (zh) * 2017-08-04 2021-04-13 青岛东海药业有限公司 凝结芽孢杆菌在制备降低血尿酸制剂中的应用
JP2020530011A (ja) 2017-08-06 2020-10-15 セカンド ゲノム インコーポレイテッド バイオ治療薬としてのストレプトコッカス・オーストラリス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ａｕｓｔｒａｌｉｓ）
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
WO2019032575A1 (en) * 2017-08-07 2019-02-14 Finch Therapeutics, Inc. TREATMENT OF LIVER DISEASE BY MODULATION OF MICROBIOMA
CN111212655A (zh) 2017-08-14 2020-05-29 赛里斯治疗公司 用于治疗胆汁淤积性疾病的组合物和方法
BR112020002419A2 (pt) 2017-08-14 2020-07-28 Axcella Health Inc. aminoácido para o tratamento de doença do fígado
TWI640314B (zh) * 2017-08-22 2018-11-11 長庚生物科技股份有限公司 戈氏副擬桿菌用於降低胰島素抗性及提升葡萄糖耐受性之用途
WO2019046401A1 (en) * 2017-08-29 2019-03-07 Evelo Biosciences, Inc. TREATMENT OF CANCER USING BLAUTIA STRAIN
EP3675833A1 (en) 2017-08-29 2020-07-08 Chr. Hansen A/S Stable capsules with fecal microbiota or a culture of microorganisms
AU2018326705A1 (en) 2017-08-30 2020-03-05 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
EP3453395B1 (en) 2017-09-08 2023-10-18 Deutsches Rheuma-Forschungszentrum Berlin Anaeroplasmatales for use in the treatment or prevention of an inflammatory disorder of the digestive system
MX2020002659A (es) 2017-09-08 2020-09-09 Evelo Biosciences Inc Vesiculas extracelulares bacterianas.
CN111132684A (zh) * 2017-09-26 2020-05-08 第二基因组股份有限公司 作为生物治疗药物的血孪生球菌
CN111970933A (zh) 2017-10-18 2020-11-20 埃斯库斯生物科技股份公司 通过施用微生物或其纯化菌株的合成生物集合体来提高禽类产量
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
FI128395B (en) * 2017-11-09 2020-04-30 Kemira Oyj Method for making a fibrous web
CN107653243B (zh) * 2017-11-15 2021-06-15 中国农业科学院农业基因组研究所 一种从肠道内容物中提取微生物宏基因组dna的方法
CA3084954A1 (en) 2017-12-05 2019-06-13 BioPlx, Inc. Methods and compositions to prevent microbial infection
CN107828705A (zh) * 2017-12-31 2018-03-23 佛山市艳晖生物科技有限公司 一株解淀粉芽孢杆菌及其在防治孤独症上的应用
TWI813620B (zh) 2018-02-02 2023-09-01 香港中文大學 糞便微生物群移植的糞便真菌微生物和治療功效
US11723934B2 (en) 2018-02-09 2023-08-15 Keio University Compositions and methods for the induction of CD8+ T-cells
JP7325106B2 (ja) * 2018-02-09 2023-08-14 Ｎｏｓｔｅｒ株式会社 リポ多糖制御性腸内細菌及びその用途
CN110211629A (zh) * 2018-02-11 2019-09-06 中国科学院昆明动物研究所 一种评估微生物群落宏基因（或普通生物群落宏遗传）多样性和相似性的概念和方法
ES3032290T3 (en) 2018-03-20 2025-07-16 Theriva Biologics Inc Intestinal alkaline phosphatase formulations
KR20200138333A (ko) * 2018-03-29 2020-12-09 세레스 테라퓨틱스, 인코포레이티드 염증성 장 질환을 치료하는 조성물 및 방법
WO2019199895A1 (en) 2018-04-10 2019-10-17 Siolta Therapeutics, Inc. Microbial consortia
WO2019200271A1 (en) 2018-04-13 2019-10-17 White Dog Labs, Inc. An improved method for selecting probiotics
KR102225939B1 (ko) * 2018-04-19 2021-03-10 주식회사 고바이오랩 신규한 Bacteroides vulgatus 균주 및 이를 유효 성분으로 하는 면역 및 대사성 질환 예방 또는 치료용 조성물
WO2019210403A1 (en) * 2018-04-30 2019-11-07 Suncor Energy Inc. Macrocyclic tetrapyrrole compounds, compositions and methods for increasing abiotic stress resistance in plants
CN113151036B (zh) 2018-05-11 2024-08-23 韩国亿诺生物有限公司 具有预防或治疗癌症的效果的新型菌株
CN112469426B (zh) 2018-05-23 2025-07-11 布莱阿姆青年大学 噬菌体组合物和试剂盒及相关方法
US11986502B2 (en) 2018-05-23 2024-05-21 Optium, LLC Bacteriophage compositions and kits and related methods
MX2020012602A (es) * 2018-05-24 2021-03-31 Seres Therapeutics Inc Composiciones bacterianas dise?adas y usos de las mismas.
US20210121511A1 (en) * 2018-05-29 2021-04-29 Unm Rainforest Innovations Virus-like particle compositions and methods of using same
WO2019236806A1 (en) * 2018-06-07 2019-12-12 Artugen Therapeutics Ltd. Methods and compositions for the treatment of c. difficile
EP3806874A1 (en) * 2018-06-14 2021-04-21 Rebiotix, Inc. Microbiota restoration therapy (mrt) compositions and methods of manufacture
CA3103064A1 (en) * 2018-06-19 2019-12-26 4D Pharma Research Ltd Dosage form comprising a live biotherapeutic product
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
EP3594321A1 (en) 2018-07-10 2020-01-15 Université catholique de Louvain Dusodibacter, a novel bacterial genus of the gastroinstestinal microbiota and uses thereof
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CA3106315A1 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
US12226433B2 (en) 2018-08-06 2025-02-18 The Johns Hopkins University Treatment of irritable bowel syndrome with molybdenum
AU2019321681A1 (en) 2018-08-17 2021-02-25 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
WO2020055547A2 (en) 2018-08-18 2020-03-19 Seed Health, Inc. Methods and compositions for honey bee health
WO2020041581A1 (en) * 2018-08-23 2020-02-27 Cornell University Methods and compositions for preventing and treating inflammatory bowel disease and nonalcoholic fatty liver disease
US11401500B2 (en) 2018-08-29 2022-08-02 Nch Corporation System, method, and composition for incubating spores for use in aquaculture, agriculture, wastewater, and environmental remediation applications
CN113728088B (zh) 2018-09-13 2025-02-14 未知君有限责任公司 治疗胃肠障碍和炎性障碍的方法和组合物
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
CN109234195A (zh) * 2018-09-28 2019-01-18 邓州市汇海农业科技有限公司 一种稻田微生物复合菌剂
KR102135195B1 (ko) * 2018-10-08 2020-07-17 아주대학교산학협력단 테트라제노코커스 할로필러스를 포함하는 베체트병 또는 헤르페스 바이러스 감염증의 예방 또는 치료용 조성물
WO2020074569A1 (en) * 2018-10-09 2020-04-16 4D Pharma Research Limited Compositions comprising bacterial strains
EP3866819A1 (en) * 2018-10-15 2021-08-25 PharmaBiome AG A method of manufacturing a consortium of bacterial strains
JP2022506726A (ja) * 2018-11-09 2022-01-17 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド ディスバイオシスの処置及び／または予防のための治療用微生物叢
KR20210125988A (ko) 2018-12-10 2021-10-19 노봄 바이오테크놀로지스, 인크. 고옥살산뇨증을 치료하기 위한 방법 및 조성물
WO2020139852A1 (en) * 2018-12-28 2020-07-02 General Probiotics, Inc. Combinations of engineered antimicrobial probiotics for treatment of gastrointestinal tract pathogens
AU2020222515B2 (en) 2019-02-15 2025-10-09 Nutrien Ag Solutions (Canada) Inc. The use of protoporphyrin IX derivatives to improve the health of plants
JP7262127B2 (ja) * 2019-02-15 2023-04-21 コンビ株式会社 新規乳酸菌およびそれを含有する組成物
CN110195027B (zh) * 2019-03-08 2022-03-01 大连理工大学 烟草节杆菌zl-1及其堆肥低温发酵菌剂的制备方法与应用
US20220184153A1 (en) * 2019-03-25 2022-06-16 The State of Israel, Ministry of Agriculture&Rural Development, Agricltural Research Oganization(ARO Method of treating bovine mastitis
WO2020198503A1 (en) * 2019-03-26 2020-10-01 The Children's Medical Center Corporation Therapeutic microbiota for the treatment and/or prevention of dysbiosis
WO2020229428A1 (en) * 2019-05-10 2020-11-19 4D Pharma Research Limited Compositions comprising bacterial strains
MX2021014335A (es) * 2019-05-23 2022-03-25 American Molecular Laboratories Inc Metodos para detectar un nivel de h. pylori en una muestra fecal.
EP3958690A4 (en) * 2019-05-31 2023-04-19 South Dakota Board of Regents PROBIOTICS TO INHIBIT ENTERIC PATHOGENS
KR20220016481A (ko) 2019-06-03 2022-02-09 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 패혈증 및 괴사성 장염 유도된 신경발달 결핍의 예방을 위한 프리바이오틱 제형
WO2021011887A1 (en) * 2019-07-17 2021-01-21 University Of Utah Research Foundation Clostridia consortia compositions and methods of treating obesity, metabolic syndrome and irritable bowel disease
BR112022000875A2 (pt) 2019-07-19 2022-03-29 Finch Therapeutics Holdings Llc Métodos e produtos para tratamento de distúrbios gastrointestinais
WO2021022066A1 (en) * 2019-07-30 2021-02-04 The Regents Of The University Of California Compositions and methods for inhibiting bacterial virulence and flim-based device and method for antibiotic susceptibility testing
CN110358849A (zh) * 2019-07-30 2019-10-22 中国医学科学院北京协和医院 源于肠道的诊断胰腺炎的生物标志物、筛选方法及其用途
CN112438995A (zh) 2019-09-04 2021-03-05 台达电子工业股份有限公司 抑制具万古霉素抗药性肠球菌的益生菌及其组合与其用途
KR20220065793A (ko) * 2019-09-12 2022-05-20 마블바이옴 인코포레이티드 마이크로바이옴을 특성화하기 위한 조성물 및 방법
WO2021061991A1 (en) 2019-09-24 2021-04-01 Prolacta Bioscience, Inc. Compositions and methods for treatment of inflammatory and immune diseases
EP4041264A1 (en) 2019-10-07 2022-08-17 Siolta Therapeutics, Inc. Therapeutic pharmaceutical compositions
EP4054609A1 (en) * 2019-11-04 2022-09-14 Vedanta Biosciences, Inc. Compositions and methods for enhancing immune checkpoint inhibitor therapy
BR112022010411A2 (pt) * 2019-11-27 2022-08-23 Seres Therapeutics Inc Composições bacterianas projetadas e usos das mesmas
KR102215592B1 (ko) * 2019-12-11 2021-02-15 주식회사 에이치이엠 신규한 락토바실러스 퍼멘텀 hem 1036 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물
US11918675B2 (en) 2019-12-16 2024-03-05 Colgate-Palmolive Company Oral care compositions
EP3838276A1 (en) * 2019-12-17 2021-06-23 Exeliom Biosciences Association of faecalibacterium prausnitzii strain cncm i-4573 with pentasa® for the treatment and prevention of gastrointestinal inflammation
TWI854077B (zh) * 2019-12-20 2024-09-01 瑞士商葛德瑪控股公司 生產肉毒桿菌毒素的方法
US12121553B2 (en) 2020-01-27 2024-10-22 General Probiotics, Inc. Compositions including probiotic bacteria for the expression and secretion of enterocins to control clostridia perfringens-induced necrotic enteritis in livestock and related methods
WO2021159068A1 (en) 2020-02-06 2021-08-12 Nch Corportion Composition and method of using germinative compounds in probiotics for inflammation reduction in humans
AU2021220800A1 (en) 2020-02-10 2022-07-07 Native Microbials, Inc. Microbial compositions and methods of use for canine enteropathy and dysbiosis
CA3177351A1 (en) * 2020-02-18 2021-08-26 Memorial Sloan-Kettering Cancer Center Methods and compositions for identifying and treating subjects at risk of poor cancer survival
WO2021167088A1 (ja) * 2020-02-21 2021-08-26 良和 中岡 肺高血圧症改善用組成物、肺高血圧症の予後予測方法、肺高血圧症の重症度判定補助方法および肺高血圧症の診断補助方法
EP4110269A4 (en) * 2020-02-28 2024-01-17 Emory University PENTAGALLOYL GLUCOSE DERIVED FROM SCHINUS PLANTS AND METHODS OF USE
TW202146036A (zh) * 2020-04-28 2021-12-16 香港中文大學 針對ｃｏｖｉｄ－１９的微生物的治療和診斷用途
WO2021221110A1 (ja) * 2020-04-29 2021-11-04 学校法人慶應義塾 Ｔｈ１細胞及び／又はＴｈ１７細胞の増殖又は活性化を誘導する小腸内細菌
GB202007452D0 (en) * 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
WO2021252632A2 (en) * 2020-06-09 2021-12-16 Flagship Pioneering, Inc. Physiologically acceptable compositions containing microorganisms or microbial products
NL2025863B1 (en) 2020-06-19 2022-02-17 Acad Medisch Ct Fecal matter for treatment of cachexia
US20230310518A1 (en) * 2020-07-28 2023-10-05 Icahn School Of Medicine At Mount Sinai Compositions and Methods for Treating Infections of the Gastrointestinal Tract
BR112023002758A2 (pt) 2020-08-14 2023-05-02 Prolacta Bioscience Inc Composições de oligossacarídeos de leite humano para uso com bacterioterapias
CN112040091B (zh) 2020-09-01 2023-07-21 先临三维科技股份有限公司 相机增益的调整方法和装置、扫描系统
IL301145A (en) * 2020-09-11 2023-05-01 Marvelbiome Inc Methods and uses of microbiome compositions
US12280037B2 (en) 2020-09-22 2025-04-22 Evofem Biosciences, Inc. Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof
KR102470808B1 (ko) * 2020-11-02 2022-11-28 주식회사 바이오미 염증성 장질환 예방 또는 치료용 조성물
MX2023006146A (es) * 2020-11-25 2023-07-31 Seres Therapeutics Inc Composiciones bacterianas diseñadas para tratar la enfermedad de injerto contra huésped.
US20240127925A1 (en) * 2021-02-03 2024-04-18 Tata Consultancy Services Limited Method and system for designing personalized therapeutics and diet based on functions of microbiome
CN114948986A (zh) * 2021-02-19 2022-08-30 星聚樊生物科技有限公司 中草药多醣及其细菌组成物改善疾病的用途
KR102373886B1 (ko) * 2021-03-26 2022-03-15 주식회사 에이치이엠파마 머신러닝 모델을 이용하여 장염 유무를 판별하는 방법 및 진단 장치
KR102373888B1 (ko) * 2021-03-26 2022-03-15 주식회사 에이치이엠파마 머신러닝 모델을 이용하여 변비 유무를 판별하는 방법 및 진단장치
CN113106042A (zh) * 2021-05-20 2021-07-13 广西壮族自治区兽医研究所 预防鸽形目念珠菌病的微生物菌剂、制剂及其制备方法和应用
NL2028324B1 (en) 2021-05-28 2022-12-12 Caelus Pharmaceuticals B V Insulin-sensitizing agent and butyrate-producing bacterium
US20240368558A1 (en) * 2021-07-30 2024-11-07 Oncomedics Compositions and methods for decontaminating and culturing a gastrointestinal tract sample
KR102583365B1 (ko) * 2021-08-11 2023-09-27 코스맥스 주식회사 마이크로코커스 안타르크티쿠스 균주 및 그의 피부 상태 개선 용도
EP4429683A1 (en) 2021-11-11 2024-09-18 Concerto Biosciences, Inc. Microbial compositions for the treatment of skin diseases
CN116135205A (zh) * 2021-11-16 2023-05-19 葡萄王生技股份有限公司 戊醣片球菌gkp4用于制备改善肌少症之口服组成物的用途
EP4183403A1 (en) * 2021-11-19 2023-05-24 Lietuvos Sveikatos Mokslu Universitetas Modification of fecal microbiota with capsules containing gram-positive bacteria
WO2023132628A1 (ko) * 2022-01-04 2023-07-13 주식회사 바이오뱅크힐링 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102438867B1 (ko) * 2022-03-11 2022-09-02 주식회사 바이오뱅크힐링 코프로코커스 캐터스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN114317368B (zh) * 2022-01-05 2022-09-09 中国水产科学研究院南海水产研究所 一种利用盐渍四生球菌改善快速发酵鱼露风味的方法
US20250170163A1 (en) * 2022-02-23 2025-05-29 Societe Des Produits Nestle S.A. Compositions and methods for reducing the occurrence of diarrhea by promoting blautia obeum in the gut microbiota
EP4514155A2 (en) * 2022-04-26 2025-03-05 Cedars-Sinai Medical Center Methanogens and prevotella as microbial convener for the treatment of diseases and diagnosis thereof
CN114965764B (zh) * 2022-05-18 2024-12-31 陕西安宁云生生物技术有限公司 便秘的诊断和治疗
CN115466690A (zh) * 2022-05-19 2022-12-13 同济大学 一种地芽孢杆菌新菌种及其培养方法和应用
AU2023319159A1 (en) * 2022-08-01 2025-02-06 Novel Biome Solutions Inc. Fecal microbiota transplant methods of manufacture
CN116790402B (zh) * 2023-01-14 2024-05-14 西北农林科技大学 一株具有抗炎特性的单形拟杆菌菌株、培养方法及应用
WO2025064408A1 (en) 2023-09-18 2025-03-27 The Broad Institute, Inc. Compositions and methods for treating cardiovascular disease
WO2025093777A1 (en) 2023-11-05 2025-05-08 Human Biome Institute S.A. Functional compositions and methods of use thereof in the treatment and recurrence prophylaxis of clostridioides difficile infection and restoration of healthy microbiota
WO2025147266A1 (en) * 2024-01-06 2025-07-10 Jose Vega Method of mitigation of death from epileptic seizures
CN118360215B (zh) * 2024-05-22 2025-03-07 吉林省农业科学院(中国农业科技东北创新中心) 一种用于降低反刍动物甲烷排放量的菌剂及其制备方法以及含有该菌剂的配合饲料

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3009864A (en) 1958-09-18 1961-11-21 Union Carbide Corp Process control
US3228838A (en) 1959-04-23 1966-01-11 Union Carbide Corp Preservation of biological substances
US3009861A (en) * 1961-01-13 1961-11-21 Alderton Gordon Isolation of bacterial spores
US3608030A (en) 1969-05-21 1971-09-21 Howard Tint Method of preparing a tablet dosage-form for the immunization of the intestinal tract with live virus preparations
US3892842A (en) * 1971-09-01 1975-07-01 Alza Corp Intrauterine contraceptive device for releasing steroid having double bond functionality
DE2414156A1 (de) * 1974-03-23 1975-09-25 Kleist Johann Georg Dr Arzneimittel zur beseitigung uraemischer symptome und verfahren zu seiner herstellung
US4077227A (en) 1976-11-12 1978-03-07 Regents Of The University Of Minnesota Method of freezing liquid material in which agglomeration is inhibited
US4205132A (en) 1978-07-17 1980-05-27 Microlife Technics, Inc. Lyophilization of bacteria
FI59925C (fi) 1980-01-11 1981-11-10 Esko Viljo Nurmi Foerfarande foer framstaellning av ett bakteriepreparat anvaendbart foer foerhindrande av salmonellainfektion hos fjaederfae
US4780987A (en) * 1983-10-25 1988-11-01 Plant Genetics, Inc. Method for the preparation of hydrated, pregerminated seeds in gel capsules
US4655047A (en) 1985-03-25 1987-04-07 I.Q.F. Inc. Process for freezing or chilling
JPS61252212A (ja) 1985-04-12 1986-11-10 Mitsubishi Petrochem Co Ltd 高吸水性ポリマ−の製造方法
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
WO1989003219A1 (en) 1987-10-12 1989-04-20 Borody Thomas J Improved method for treatment of gastrointestinal disorders
US5045446A (en) 1988-08-26 1991-09-03 Cryopharm Corporation Lyophilization of cells
WO1990001335A1 (en) 1988-08-02 1990-02-22 Borody Thomas J Treatment of gastro-intestinal disorders
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
GB2233343B (en) 1989-06-30 1993-07-07 Farmos Oy A bacterial preparation for use in poultry
JP2961182B2 (ja) 1990-03-09 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
US5436002A (en) 1991-01-29 1995-07-25 Mycogen Corporation Bacillus thuringiensisisolate PS201T6 toxin
RU2035186C1 (ru) 1992-07-09 1995-05-20 Семен Рафаилович Резник Профилактический биопрепарат споролакт
ATE200625T1 (de) 1992-10-09 2001-05-15 Advanced Tissue Sciences Inc Leberreservezellen
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
WO1997008598A1 (de) 1995-08-25 1997-03-06 Gff Technopark Verfahren zur simultanen, digitalen phasenempfindlichen detektion von zeitaufgelösten, quasi-gleichzeitig erfassten datenarrays eines periodisch stimulierten systems
US5851545A (en) * 1995-08-25 1998-12-22 Sandoz Ltd. Insecticidal matrix and process for preparation thereof
EP0952773B1 (en) * 1995-09-15 2005-11-23 Dale N. Gerding Methods and compositions for prevention and treatment of clostridium difficile-associated diseases
AUPO430496A0 (en) 1996-12-19 1997-01-23 Arnott's Biscuits Limited Prebiotics and probiotics
US6024370A (en) 1997-07-03 2000-02-15 Rockshox, Inc. Damping cartridge for high performance suspension systems
US5965128A (en) 1997-08-13 1999-10-12 University Of Georgia Research Foundation Inc. Control of enterohemorrhagic E. coli 0157:H7 in cattle by probiotic bacteria and specific strains of E. coli
US5951977A (en) 1997-10-14 1999-09-14 The United States Of America, As Represented By The Secretary Of Agriculture Competitive exclusion culture for swine
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6589771B1 (en) 1999-10-28 2003-07-08 Immunom Technologies, Inc. Methods for arousing dormant bacteria
US20030118547A1 (en) 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
WO2001058465A2 (en) 2000-02-10 2001-08-16 Gregor Reid Probiotic therapy for newborns
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20020013270A1 (en) * 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
AU2001289438A1 (en) * 2000-09-22 2002-04-02 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
IL156213A0 (en) 2000-11-30 2003-12-23 Bio Balance Corp Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
KR100437497B1 (ko) * 2001-03-07 2004-06-25 주식회사 프로바이오닉 로타바이러스 및 유해 미생물 억제 활성을 가지는 신규내산성 락토바실러스 루테리 프로바이오-16 및 이를함유하는 생균활성제
CN1678735A (zh) 2001-05-04 2005-10-05 佛罗里达大学研究基金会有限公司 来源于细菌的丙酮酸脱羧酶(pdc)基因的克隆和测序及其用途
ITMI20011632A1 (it) 2001-07-27 2003-01-27 Sanofi Synthelabo Composizione solida contenente spore di batteri non patogeni del genere bacillus
GB0130789D0 (en) 2001-12-21 2002-02-06 King S College London Application of spores
US8383342B2 (en) 2002-04-24 2013-02-26 The University Of North Carolina At Greensboro Compositions, products, methods and systems to monitor water and other ecosystems
GB0212975D0 (en) 2002-06-06 2002-07-17 Mars Uk Ltd Mammalian animal composition
AU2002951692A0 (en) 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
AU2003303894A1 (en) 2003-01-30 2004-08-30 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
CA2559596A1 (en) 2003-03-13 2004-11-25 Universite De Moncton (Bureau De Soutien A L'innovation) Antioxidant producing bacterium and uses thereof
DK1631312T3 (da) 2003-04-23 2009-01-19 Medarex Inc Sammensætning og fremstillingsmåde til behandling af inflammatorisk tarmsygdom
US7261861B2 (en) 2003-04-24 2007-08-28 Haemoscope Corporation Hemostasis analyzer and method
EP1473370A3 (en) 2003-04-24 2005-03-09 BioMerieux, Inc. Genus, group, species and/or strain specific 16S rDNA Sequences
WO2004104175A2 (en) 2003-05-14 2004-12-02 University Of Georgia Research Foundation, Inc. Probiotic bacteria and methods
JP2007518693A (ja) 2003-08-18 2007-07-12 ザ バイオ バランス コーポレイション 安定な液体プロバイオティクス組成物、その調製および適用
US20050048515A1 (en) 2003-08-29 2005-03-03 Garner Bryan E. Methods for detecting and quantifying specific probiotic microorganisms in animal feed
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
HUE024565T2 (hu) 2004-02-03 2016-02-29 Prevtec Microbia Inc Élõ baktériumok alkalmazása növekedésserkentésre állatokban
US7632520B2 (en) 2004-02-16 2009-12-15 Sanjeev Khandelwal Synergistic antibacterial formulation and to a method of making the same
US7854927B2 (en) 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders
EP2280085A3 (en) 2004-11-01 2011-02-23 George Mason University Compositions and methods for diagnosing colon disorders
EP1812585B1 (en) 2004-11-01 2014-08-06 Erber Aktiengesellschaft Bacteriophages as selective agents
US20060188523A1 (en) 2005-01-10 2006-08-24 Zhiheng Pei Methods for diagnosing and treating chronic tonsillitis
US7993667B2 (en) 2005-03-25 2011-08-09 Kimberly-Clark Worldwide, Inc. Methods of manufacturing a medicated tampon assembly
PL1885383T3 (pl) 2005-05-31 2017-06-30 Iams Europe B.V. Kocie probiotyczne bifidobakterie
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
DK3067057T3 (da) 2005-09-28 2023-02-13 Nordic Rebalance As Probiotisk fermenteret cerealiesammensætninger til anvendelse ved behandling af gastrointestinale lidelser forårsaget af pro-inflammatoriske bakterier
US8968721B2 (en) * 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
WO2007136553A2 (en) 2006-05-18 2007-11-29 Biobalance Llc Bacterial strains, compositions including same and probiotic use thereof
US20090324638A1 (en) * 2006-06-12 2009-12-31 Biopeptides Corp. Live bacterial vaccine
JP5019563B2 (ja) * 2006-06-16 2012-09-05 旭化成ケミカルズ株式会社 腸内細菌賦活剤
JP2009541298A (ja) 2006-06-20 2009-11-26 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 胃腸障害を処置するための電子カプセル
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EE05459B1 (et) 2006-12-08 2011-08-15 Tartu �likool Sporogeense Bacillus smithii tvi TBMI12 MSCL P737 ja selle endospooride kasutamine probiootikumina, toidulisandina ning probiootiline kompositsioon
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
WO2008083157A2 (en) 2006-12-29 2008-07-10 Washington University In St. Louis Altering pgc-1alapha, ampk, fiaf, or the gastrointestinal microbiota as a means to modulate body fat and/or weight loss in a subject
CA2699550C (en) * 2007-09-12 2020-08-18 Targanta Therapeutics Corp. Method of inhibiting clostridium difficile by administration of oritavancin
EP2207277A4 (en) 2007-10-16 2015-08-12 Fujitsu Ltd RELAY STATION DEVICE, DEVICE STATION DEVICE, WIRELESS COMMUNICATION SYSTEM AND LOAD DISTRIBUTION METHOD
US8236508B2 (en) 2008-01-29 2012-08-07 Drexel University Detecting and measuring live pathogens utilizing a mass detection device
US8021654B2 (en) * 2008-03-14 2011-09-20 Danisco A/S Methods of treating pigs with Bacillus strains
JP2011527177A (ja) 2008-04-01 2011-10-27 メタメトリックス クリニカル ラボラトリー 胃腸微生物叢の監視プロセスおよび方法
CN101264107A (zh) * 2008-05-09 2008-09-17 东北制药集团公司沈阳第一制药厂 地衣芽孢杆菌药物组合物及其制剂
CN102940652B (zh) 2008-05-28 2015-03-25 青岛东海药业有限公司 两形真杆菌制剂及其应用
CN102119330B (zh) 2008-07-15 2014-02-12 梅坦诺米克斯保健有限公司 诊断胃改道手术及其相关状况的工具和方法
WO2010024251A1 (ja) 2008-08-26 2010-03-04 オリンパス株式会社 糞便試料の調製方法、糞便試料調製用溶液、及び採便用キット
WO2010030997A1 (en) 2008-09-12 2010-03-18 The Washington University Regulating intestinal microbiota dependent signaling as a means to modulate body fat and/or weight loss
WO2010036876A2 (en) 2008-09-25 2010-04-01 New York University Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
CA2779413A1 (en) * 2008-11-03 2010-06-03 Tufts University Methods and compositions for inhibiting clostridium difficile spore germination and outgrowth
FR2938057B1 (fr) 2008-11-05 2013-05-17 Patrick Wozna Doseur a delta de pression
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
IT1393931B1 (it) * 2009-02-25 2012-05-17 Neuroscienze Pharmaness S C A R L Composizione di spore di batteri non patogeni
US20120128633A1 (en) 2009-04-30 2012-05-24 Campagnie Gervaise Donone Use of collinsella aerofaciens for reducing bloating
PL2419114T5 (pl) 2009-05-01 2019-09-30 Uas Laboratories Llc Kompozycje bakteryjne do profilaktyki i leczenia choroby degeneracyjnej
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
US20120264637A1 (en) 2009-06-26 2012-10-18 The Regents Of The University Of California Methods and systems for phylogenetic analysis
DK2446062T3 (da) 2009-06-26 2014-10-06 Univ California Fremgangsmåder og systemer til phylogenetisk analyse
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
CA2770099A1 (en) 2009-08-18 2011-02-24 Nestec S.A. A nutritional composition comprising lactococcus strains and reducing allergy symptoms, especially in infants and children.
WO2011022542A2 (en) 2009-08-19 2011-02-24 Puretech Ventures, Llc Administration of factors normally present in a microbial niche to improve health
US20120149584A1 (en) 2009-08-21 2012-06-14 Bernat Olle Methods of diagnosing and treating microbiome-associated disease using interaction network parameters
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
JP2013505289A (ja) 2009-09-23 2013-02-14 トーマス・ジュリアス・ボロディ 腸管感染症の治療法
WO2011043654A1 (en) 2009-10-05 2011-04-14 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
WO2011046616A2 (en) 2009-10-15 2011-04-21 New York University Methods for modulating bacterial infection
WO2011060123A1 (en) 2009-11-12 2011-05-19 Nestec S.A. Nutritional composition for promoting gut microbiota balance and health
CA2785658C (en) 2009-12-31 2017-10-24 Ira Milton Trachtman Compositions and method for treatment and prophylaxis of inflammatory bowel disease
HRP20220751T1 (hr) * 2010-02-01 2022-09-02 Rebiotix, Inc. Bakterioterapija clostridium difficile kolitisa
US9492487B2 (en) 2010-02-01 2016-11-15 Matthew Ryan Garner Microbial product containing multiple microorganisms
WO2011103123A2 (en) 2010-02-16 2011-08-25 Arizona Technology Enterprises Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities
AU2011223049B2 (en) 2010-03-01 2015-06-18 Institut National De La Recherche Agronomique Method of diagnostic of inflammatory bowel diseases
CN102939392A (zh) 2010-03-01 2013-02-20 国家农艺研究院 肥胖的诊断方法
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
WO2011113801A1 (en) 2010-03-16 2011-09-22 Universiteit Gent Use of clostridium perfringens strain 23 to protect against necrotic enteritis
US8951512B2 (en) 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
HRP20160805T1 (hr) 2010-07-06 2016-08-12 Glaxosmithkline Biologicals Sa Imuniziranje velikih sisavaca malim dozama rna
US9005601B2 (en) 2010-07-16 2015-04-14 The Board Of Trustees Of The University Of Arkansas Methods and compositions including spore-forming bacteria for increasing the health of animals
FI20105825A7 (fi) 2010-07-26 2012-01-27 Suomen Punainen Risti Veripalvelu Veriryhmästatuksen käyttö III
NZ607043A (en) 2010-08-04 2015-05-29 Borody Thomas J Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
BR112013003895A2 (pt) 2010-08-19 2016-07-12 Merz Pharma Gmbh & Co Kgaa composição de enchimento e seu uso, processo para a preparação da composição de enchimento, kit e dispositivo de injeção
WO2012024638A2 (en) 2010-08-20 2012-02-23 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
WO2012033814A2 (en) 2010-09-10 2012-03-15 Viropharma Incorporated Environmental clostridial bacteriotherapy and related formulations and methods of manufacture and use
AU2011313763A1 (en) 2010-10-04 2013-05-30 Emma Allen-Vercoe Detection of Fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer
EP2637650A2 (en) 2010-11-10 2013-09-18 National Jewish Health Methods to test allergic conditions
US20120064592A1 (en) 2011-01-26 2012-03-15 Qteros, Inc. Biocatalysts synthesizing deregulated cellulases
CN103491969A (zh) 2011-02-09 2014-01-01 拉维沃公司 恢复和重建肠道微生物群的合生素组合物
WO2012116289A2 (en) 2011-02-25 2012-08-30 Tricorder Diagnostics, Llc Microbial signatures as indicators of radiation exposure
WO2012122522A2 (en) 2011-03-09 2012-09-13 Washington University Cultured collection of gut microbial community
CN103561752B (zh) * 2011-03-09 2016-04-20 明尼苏达大学评议会 用于移植结肠微生物群的组合物和方法
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
US9411937B2 (en) 2011-04-15 2016-08-09 Verinata Health, Inc. Detecting and classifying copy number variation
US20120278201A1 (en) 2011-04-26 2012-11-01 Dwolla Corp. Location transaction processing system
US20120276056A1 (en) 2011-04-26 2012-11-01 Wieslaw Janusz Bochenek Method for Use of Biologic Agents Including Live or Dormant Forms of Bacteria and other organisms in Treating Infections, Inflammation and Other Diseases of Distal Small Intestine and Large Intestine
US20120284637A1 (en) 2011-05-02 2012-11-08 John Edward Boyer Unified Virtual Group Calendar System
WO2012159023A2 (en) 2011-05-19 2012-11-22 Virginia Commonwealth University Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
US9579353B2 (en) 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
US20130017999A1 (en) 2011-07-14 2013-01-17 Marc Fremont Methods and Compositions for Evaluating and/or Treating Chronic Immune Diseases
US20130022575A1 (en) 2011-07-19 2013-01-24 Microbial Rx Systems and methods of replacing intestinal flora
US20140348811A1 (en) 2011-07-27 2014-11-27 Max International, Llc Compositions comprising sugar-cysteine products
WO2013019896A1 (en) 2011-08-01 2013-02-07 Symbiotix Biotherapies, Inc. Platform for identifying and/or characterizing immunomodulatory agents
AU2012302364B2 (en) 2011-08-30 2016-07-28 Caelus Lifesciences IP B.V. Method for preventing and/or treating insulin resistance
US20140363397A1 (en) 2011-09-14 2014-12-11 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
WO2013066369A2 (en) 2011-10-03 2013-05-10 The Regents Of The University Of Michigan Methods for detecting graft-versus-host disease
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2013053836A1 (en) 2011-10-11 2013-04-18 Quantum Pharmaceuticals Sa Composition comprising anaerobically cultivated human intestinal microbiota
US10238694B2 (en) 2011-12-01 2019-03-26 The University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
GB201201766D0 (en) 2012-02-01 2012-03-14 Imp Innovations Ltd Method
WO2013166031A1 (en) 2012-04-30 2013-11-07 The Washington University Method of isolating and characterizing microorganisms that are targets of host immune responses
EP2850202B1 (en) 2012-05-18 2020-03-11 Genome Research Limited Methods and groups
DK2854850T3 (da) 2012-05-25 2021-08-30 Sloan Kettering Inst Cancer Res Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
EP2684469A1 (en) 2012-07-13 2014-01-15 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Methods for strengthening and assessment of the natural defence of the colon against C. difficile overgrowth
US20140112985A1 (en) * 2012-10-22 2014-04-24 Polonez Therapeutics Llc Method of prevention and treatment of clostridium difficile infection
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP3628161B1 (en) 2012-11-23 2023-04-05 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
CA2899926C (en) * 2013-02-04 2025-11-18 Seres Therapeutics, Inc. DIGESTIVE TUBE FILLING COMPOSITIONS
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
HK1220495A1 (zh) 2013-03-14 2017-05-05 Seres Therapeutics, Inc. 从材料和组合物中检测和富集病原体的方法
EP2967077A4 (en) 2013-03-15 2016-09-14 Seres Therapeutics Inc NETWORK-BASED MICROBIAL COMPOSITIONS AND METHOD
WO2014177667A1 (en) 2013-05-03 2014-11-06 Nestec S.A. Lachnospiraceae in the gut microbiota and association with body weight
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
CA2949232A1 (en) 2014-05-19 2015-11-26 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing clostridium difficile infection
FI3223835T3 (fi) 2014-11-25 2025-06-16 Memorial Sloan Kettering Cancer Center Suolen mikrobisto ja gvhd
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
RU2018103081A (ru) 2015-07-08 2019-08-08 Серес Терапеутикс, Инк. Способы лечения колитов
KR20180083894A (ko) 2015-11-24 2018-07-23 세레스 테라퓨틱스, 인코포레이티드 설계된 박테리아 조성물
EP3379935A4 (en) 2015-11-25 2019-08-28 Memorial Sloan-Kettering Cancer Center METHOD AND COMPOSITIONS FOR REDUCING VANCOMYCIN RESISTANT ENTEROKOKKEN
WO2017160711A1 (en) 2016-03-14 2017-09-21 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法

Also Published As

Publication number Publication date
CN105451561A (zh) 2016-03-30
US20160199423A1 (en) 2016-07-14
EP2956006A4 (en) 2017-02-22
EP3587558A2 (en) 2020-01-01
CN110917220A (zh) 2020-03-27
WO2014121302A2 (en) 2014-08-07
MX2015009991A (es) 2016-02-05
US20180200310A1 (en) 2018-07-19
MX369877B (es) 2019-11-25
EP2953474A2 (en) 2015-12-16
KR20150115888A (ko) 2015-10-14
EP2951285A1 (en) 2015-12-09
US9585921B2 (en) 2017-03-07
US9446080B2 (en) 2016-09-20
JP2024045100A (ja) 2024-04-02
EP3584308A3 (en) 2020-03-04
JP6942745B2 (ja) 2021-09-29
KR20230110367A (ko) 2023-07-21
EP2953474A4 (en) 2016-12-28
AU2020260564A1 (en) 2020-11-26
MX2019014045A (es) 2020-02-05
HK1219022A1 (zh) 2017-03-24
CA2899926A1 (en) 2014-08-07
US20160158294A1 (en) 2016-06-09
AU2020202312A1 (en) 2020-04-23
EP2951285A4 (en) 2016-10-26
RU2664479C2 (ru) 2018-08-17
US20140328803A1 (en) 2014-11-06
WO2014121298A2 (en) 2014-08-07
JP2019104742A (ja) 2019-06-27
BR122021010444B1 (pt) 2022-07-12
AU2014212004A1 (en) 2015-09-24
US20160184370A1 (en) 2016-06-30
EP2956006A2 (en) 2015-12-23
US9855303B2 (en) 2018-01-02
AU2014212003B2 (en) 2020-01-02
US20170196914A1 (en) 2017-07-13
KR102222273B1 (ko) 2021-03-08
US20190099455A1 (en) 2019-04-04
US20220249578A1 (en) 2022-08-11
US11185562B2 (en) 2021-11-30
US20190192581A1 (en) 2019-06-27
US10064901B2 (en) 2018-09-04
AU2014212003A1 (en) 2015-09-24
US9180147B2 (en) 2015-11-10
US20150093360A1 (en) 2015-04-02
US11730775B2 (en) 2023-08-22
WO2014121298A3 (en) 2014-10-09
CA2899925A1 (en) 2014-08-07
JP2016509002A (ja) 2016-03-24
US20160243172A1 (en) 2016-08-25
WO2014121301A1 (en) 2014-08-07
AU2014212003A8 (en) 2015-10-22
AU2014212004B2 (en) 2018-09-20
US10064900B2 (en) 2018-09-04
HK1218837A1 (zh) 2017-03-17
HK1218559A1 (zh) 2017-02-24
CA2899926C (en) 2025-11-18
US10967011B2 (en) 2021-04-06
US20240050490A1 (en) 2024-02-15
JP2019116488A (ja) 2019-07-18
US20210244774A1 (en) 2021-08-12
AU2020202312B2 (en) 2022-11-24
JP6908332B2 (ja) 2021-07-28
AU2024202421A1 (en) 2024-06-27
EP3584308A2 (en) 2019-12-25
US9011834B1 (en) 2015-04-21
EP3587558A3 (en) 2020-03-04
AU2023201132A1 (en) 2023-06-01
JP7409743B2 (ja) 2024-01-09
JP2016509003A (ja) 2016-03-24
US20250000915A1 (en) 2025-01-02
WO2014121302A3 (en) 2014-10-09
BR112015018625A2 (pt) 2017-09-19
AU2014212003C1 (en) 2020-07-16
JP2021181440A (ja) 2021-11-25
KR20210024683A (ko) 2021-03-05
AU2018282348A1 (en) 2019-01-17
RU2015137399A (ru) 2017-03-10
NZ711771A (en) 2016-11-25
KR102553134B1 (ko) 2023-07-07

Similar Documents

Publication Publication Date Title
JP7409743B2 (ja) 病原性細菌生育の抑制のための組成物および方法
JP7473285B2 (ja) 相乗作用のある細菌組成物ならびにその製造及び使用方法
US11666612B2 (en) Network-based microbial compositions and methods
US20210169946A1 (en) Synergistic Bacterial Compositions and Methods of Production and Use Thereof
EP3628161B1 (en) Synergistic bacterial compositions and methods of production and use thereof
JP2016519664A5 (OSRAM)

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20151022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170206

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20170612

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190206

R150 Certificate of patent or registration of utility model

Ref document number: 6479685

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250